Esophageal involvement in chronic graft-versus-host disease

Chronic graft-versus-host disease (cGVHD) can affect the oesophagus after an allogeneic stem-cell or bone-marrow transplant. The condition develops when donor immune cells attack the recipient’s tissues, causing inflammation, scarring and impaired movement through the upper gastrointestinal tract. Oesophageal disease is less visible than skin or mouth involvement, yet it can substantially affect eating, hydration, nutrition and quality of life.

For Australian patients, care is usually coordinated through a transplant service in a major centre such as Sydney, Melbourne, Brisbane, Adelaide or Perth, with local GPs, dietitians and speech pathologists contributing to follow-up. The clinical principles discussed through specialist education, including the scientific work associated with ISDE 2021, remain relevant: identify swallowing problems early, investigate competing causes and match treatment to the severity of tissue injury.

How chronic graft-versus-host disease affects the oesophagus

Oesophageal cGVHD may cause inflammation of the lining, reduced lubrication and progressive fibrosis. Scar tissue can narrow the lumen, while abnormal muscle function may interfere with the coordinated movement of food towards the stomach. Some patients experience a dry mouth and painful oral ulcers at the same time, making swallowing particularly difficult.

Symptoms can involve solids, liquids or both. Food may feel stuck behind the breastbone, and patients may avoid meat, bread, raw vegetables or other dry foods. Reflux, chest discomfort, coughing during meals and unexplained weight loss can accompany the disorder. These symptoms are not specific to cGVHD, so infection, medication injury, peptic stricture, eosinophilic oesophagitis and malignancy must also be considered.

A patient who has recently undergone transplantation may have altered immunity and a complex medication list. Oesophageal pain can reflect candidiasis or viral infection, while tablets such as doxycycline, iron or certain anti-inflammatory medicines can irritate the mucosa. A careful history is therefore as important as the endoscopic appearance.

Recognising symptoms before nutrition deteriorates

Dysphagia is often gradual. Patients may first take longer to finish meals, drink repeatedly while eating or choose soft foods without reporting a problem. In Australia, a person who normally manages a barbecue meal, crusty bread or takeaway food may quietly stop eating these familiar foods. A change in eating habits can be an early clinical signal.

Urgent assessment is warranted for food bolus obstruction, inability to swallow fluids, dehydration, vomiting blood, black stools, severe chest pain or rapidly worsening swallowing. Recurrent coughing or a wet voice during meals may indicate aspiration and should prompt speech pathology review.

Signs that deserve prompt review

• Food sticking in the chest or throat
• Progressive difficulty with meat, bread or tablets
• Painful swallowing, reflux or meal-related coughing
• Weight loss, dehydration or reduced urine output

Useful details to record

• Whether symptoms affect solids, liquids or both
• The duration and speed of progression
• Foods avoided and the amount of fluid needed to swallow
• Current immunosuppression, antibiotics and antifungal treatment

Investigating swallowing and mucosal injury

Assessment commonly begins with a transplant physician, gastroenterologist or upper gastrointestinal specialist. Endoscopy can identify ulcers, friability, narrowing, rings and other causes of dysphagia, while biopsies may help exclude infection or alternative inflammatory disorders. A normal-looking oesophagus does not always exclude functional impairment.

A contrast swallow can show strictures, delayed transit or abnormal motility. Videofluoroscopic swallowing assessment is useful when aspiration is suspected, particularly in patients with neurological complications, severe oral cGVHD or general weakness. High-resolution manometry may be considered when symptoms persist but endoscopy and imaging do not explain them.

Infection screening should reflect the patient’s immune status and local practice. Australian transplant units follow specialist protocols, while medicines and devices are regulated by the Therapeutic Goods Administration. Financial access can also influence care: some investigations and medicines may be available through Medicare or the Pharmaceutical Benefits Scheme, whereas private endoscopy, travel and dietetic products may create additional costs.

Treating inflammation, narrowing and nutritional risk

Management depends on the dominant problem. Systemic corticosteroids or other immunosuppressive therapy may be adjusted when oesophageal cGVHD is part of broader active disease. Topical therapy directed at the mouth and swallowing pathway can help selected patients, but treatment should be prescribed by the transplant team because infection risk and drug interactions are significant.

A fixed stricture may require careful endoscopic dilation, often over more than one session. Dilation carries risks, including perforation, so it should be performed by an experienced gastroenterology team. Reflux control, adequate hydration and treatment of documented fungal or viral infection are important supportive measures.

Nutrition should be addressed early rather than after substantial weight loss. Australian dietitians may recommend soft, moist, high-protein foods that suit local eating patterns, such as stewed vegetables, yoghurt, eggs, minced meat with sauce or fortified soups. Commercial oral nutrition supplements can be useful, although taste, cost and PBS eligibility vary. Enteral feeding may be considered when oral intake is unsafe or insufficient.

Coordinating care after transplantation

Oesophageal cGVHD is rarely managed by one clinician. The transplant physician monitors systemic disease and immunosuppression, the gastroenterologist investigates mucosal injury and strictures, and the speech pathologist assesses swallowing safety. A dietitian can calculate energy and protein needs, while a pharmacist checks interactions and adherence.

Patients living outside capital cities may travel long distances to a transplant centre. Telehealth can support follow-up, but new dysphagia, suspected obstruction or dehydration requires in-person assessment. Clear communication between the metropolitan service and the local GP helps prevent delays, especially when prescriptions, pathology and hospital discharge plans cross state health systems.

Patients should receive practical advice about eating slowly, taking small bites, remaining upright after meals and following medication instructions. Tablets should not be crushed unless a pharmacist confirms that it is safe. Australian privacy and health-record requirements also mean that information sharing between public hospitals, private specialists and community providers should be appropriately documented and authorised.

Matching presentation to the next clinical step

Early reporting gives clinicians more options and may prevent avoidable malnutrition, aspiration and hospitalisation. The practical takeaway is to treat any new or progressive swallowing change after allogeneic transplantation as a reason to contact the transplant team promptly, while maintaining hydration and choosing safe, nourishing textures until assessment is arranged.